USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA)AS MONOIMMUNOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKING AGENTS FOR SOLID TUMORS

Title:

USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA)AS MONOIMMUNOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKING AGENTS FOR SOLID TUMORS

Document Type and Number:

WIPO Patent Application WO/2016/144564

Kind Code:

A9

More Like This:

JP4896043	Materials and methods for improved vaccination strategies
JP2015061876	MODIFIED VACCINIA VIRUS ANKARA FOR VACCINATION OF NEONATE
JP3046318	[Title of Invention] Ribozyme

Inventors:

DENG LIANG (US)
SHUMAN STEWART (US)
WOLCHOK JEDD D (US)
MERGHOUB TAHA (US)
DAI PEIHONG (US)
WANG WEIYI (US)

Application Number:

PCT/US2016/019663

Publication Date:

November 03, 2016

Filing Date:

February 25, 2016

Export Citation:

Click for automatic bibliography generation Help

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER (US)

International Classes:

A61K39/285; A61K39/12; A61K39/275; A61P35/00

Attorney, Agent or Firm:

GOGORIS, Adda C. (One Barker AvenueFifth Floo, White Plains NY, US)

Download PDF:

View/Download PDF PDF Help

Previous Patent: USER INTERFACE USING A ROTATABLE INPUT MECHANISM

Next Patent: METHOD FOR MONITORING MICROBIOLOGICALLY INDUCED CORROSION ON METAL SURFACES